CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 110 enrolled
Drug / intervention
Subcutaneous injection of TAK-850 +1 moredrug
Likely dose
Subcutaneous injection of TAK-850 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02313155
NCT02313155Phase 2Completed
CompareCT.gov

A Randomized Double Blind Parallel-Group Comparative Phase 1/2 Study to Evaluate the Safety and Immunogenicity of a Single Subcutaneous Injection of TAK-850 in Healthy Adult Subjects

Takeda·interventional·Posted Dec 9, 2014·Updated Feb 17, 2016

In Brief

A Phase 2 clinical trial evaluating Subcutaneous injection of TAK-850 and Intramuscular injection of TAK-850 for Influenza Infection. Completed, enrolled 110 participants.

Detailed Summary

The purpose of this study is to evaluate the safety and immunogenicity of a single subcutaneous injection of TAK-850 as compared to intramuscular injection of TAK-850 in healthy Japanese adults

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza Infection
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 9, 2014
Enrollment StartDec 1, 2014
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.6 years ago

Interventions

Subcutaneous injection of TAK-850drug

TAK-850 0.5 mL, Subcutaneous injection

Intramuscular injection of TAK-850drug

TAK-850 0.5 mL, Intramuscular injection